Coronary/Structural Heart

NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China

ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced that it has successfully treated the first patients in Asia using the NeoChord procedure at Queen […]

Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet

SHANGHAI, Sept. 3, 2018 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®”, HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) which conducted a multi-center, randomized controlled trial called TARGET AC has been published online in The Lancet, a world leading medical journal currently ranked second […]

FAST-FFR Pivotal Trial Added to TCT 2018 Late-Breaking Clinical Trial Program

KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego. FAST-FFR trial data will be presented in the Main Arena during the late-breaking science session that begins at 12 noon […]

XBiotech Announces Decisive Results on the Potential Role of Interleukin-1 Alpha in Heart Attack Risk

AUSTIN, Texas, August 27, 2018 (GLOBE NEWSWIRE) – XBiotech Inc. (NASDAQ: XBIT) today announced the release of results indicating that leukocyte-derived Interleukin-1 alpha (IL-1⍺) is the cause clots that can cause a heart attack or stroke. The research was led by a world-renowned cardiovascular researcher, Dr. Peter Libby, Professor Mallinckrodt of […]

European Society of Cardiology incorporates iFR technology into updated guidelines for revascularization

AMSTERDAM and MUNICH, Aug. 28, 2018 /PRNewswire/ — Royal Philips (NYSE : PHG , AEX: PHIA), a global leader in health technology, today announced that the European Society of Cardiology has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) […]

Janssen Announces Results from MARINER and COMMANDER HF Studies

MUNICH, Aug. 27, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the results of the Phase 3 MARINER and COMMANDER HF (heart failure) studies, which were presented this week at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The New England Journal of Medicine. In both studies, there was no […]

HeartFlow Analysis Enables Physicians to Confidently and Safely Differentiate Patients in Need of Invasive Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease

MUNICH–(BUSINESS WIRE)–Late-breaking data published and presented today confirm that the non-invasive HeartFlow®FFRct Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who can be managed with medications alone. The ADVANCE Registry was published in the European Heart Journal (EHJ) and the Aarhus University Hospital […]

Corvia Medical Announces Strong Positive One-Year Data From REDUCE LAP-HF I Randomized, Sham-Controlled Clinical Trial

MUNICH, Aug. 27, 2018 /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). The IASD is the world’s first transcatheter device for heart failure with preserved […]

Cerner and Duke Clinical Research Institute Collaborate on Cardiac Risk App

KANSAS CITY, Mo., Aug. 23, 2018 (GLOBE NEWSWIRE) — Cerner, a global leader in health care technology, collaborated with Duke Clinical Research Institute to develop an atherosclerotic cardiovascular disease (ASCVD) Risk Calculator app, designed as a tool to increase communication between the person and their doctor about ways to live […]